Christine Grady

Christine Grady

Auto-generated profile, based on publicly available information

Christine Grady

National Institutes of Health

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EHElizabeth Horstmann
Elizabeth Horstmann
MMMary S. McCabe
Mary S. McCabe
LGLouise Grochow
Louise Grochow
SYSeiichiro Yamamoto
Seiichiro Yamamoto
LRLarry Rubinstein
Larry Rubinstein
CGChristine Grady
Christine Grady
Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in current phase 1 oncology trials.

26 February 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
CGChristine Grady
Christine Grady
The author summarizes emerging standards for informed consent as the underpinning of ethical research in humans.

25 August 2015 in The American Journal of Bioethics
Verified
Journal Article
Closed access
CGChristine Grady
Christine Grady
LELisa Eckstein
Lisa Eckstein
BBBen Berkman
Ben Berkman
DBDan Brock
Dan Brock
RCRobert Cook-Deegan
Robert Cook-Deegan
DWDavid Wendler
David Wendler
Different types of consent are used to obtain human biospecimens for future research. This variation has resulted in confusion regarding what research is permitted, inadvertent constraints on future research, and research proceeding without consent. The National Institutes of Health (NIH) Clinical Center's Department of Bioethics held a workshop to consider the ethical acceptability of addressing these concerns by using broad consent for future research on stored biospecimens. Multiple bioethics scholars, who have written on these issues, discussed the reasons for consent, the range of consent strategies, and gaps in our understanding, and concluded with a proposal for broad initial consent coupled with oversight and, when feasible, ongoing provision of information to donors. This article describes areas of agreement and areas that need more research and dialogue. Given recent proposed changes to the Common Rule, and new guidance regarding storing and sharing data and samples, this is an important and timely topic.

1 July 2005 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CGChristine Grady
Christine Grady
Offering payment to clinical research subjects, in an effort to enhance recruitment by providing an incentive to take part or enabling subjects to participate without financial sacrifice, is a common yet uneven and contentious practice in the US. Concern exists regarding the potential for payment to unduly influence participation and thus obscure risks, impair judgment, or encourage misrepresentation. Heightening these concerns is the participation not only of adults but also of children in pediatric research trials. Thorough assessment of risks, careful eligibility screening, and attention to a participant’s freedom to refuse all serve to reduce the possibility of compensation adversely affecting the individual and/or the study. Institutional review boards currently evaluate payment proposals with minimal guidance from federal regulations. Here, reasons for providing payment, payment models, ethical concerns, and areas for further research are examined.

1 March 2011 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Closed access
LALura Abbott
Lura Abbott
CGChristine Grady
Christine Grady
Institutional review boards (IRBs) are integral to the U.S. system of protection of human research participants. Evaluation of IRBs, although difficult, is essential. To date, no systematic review of IRB studies has been published. We conducted a systematic review of empirical studies of U.S. IRBs to determine what is known about the function of IRBs and to identify gaps in knowledge. A structured search in PubMed identified forty-three empirical studies evaluating U.S. IRBs. Studies were included if they reported an empirical investigation of the structure, process, outcomes, effectiveness, or variation of U.S. IRBs. The authors reviewed each study to extract information about study objectives, sample and methods, study results, and conclusions. Empirical evidence collected in forty-three published studies shows that for review of a wide range of types of research, U.S. IRBs differ in their application of the federal regulations, in the time they take to review studies, and in the decisions made. Existing studies show evidence of variation in multicenter review, inconsistent or ambiguous interpretation of the federal regulations, and inefficiencies in review. Despite recognition of a need to evaluate effectiveness of IRB review, no identified published study included an evaluation of IRB effectiveness. Multiple studies evaluating the structure, process, and outcome of IRB review in the United States have documented inconsistencies and inefficiencies. Efforts should be made to address these concerns. Additional research is needed to understand how IRBs accomplish their objectives, what issues they find important, what quality IRB review is, and how effective IRBs are at protecting human research participants.

1 November 2015 in Chest
Verified
Journal Article
Closed access
CGChristine Grady
Christine Grady